Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jul;61(7):1180-3.
doi: 10.1002/pbc.24971. Epub 2014 Jan 30.

Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma

Atmaram S Pai Panandiker  1 , J Karen Wong, Michele A Nedelka, Shengjie Wu, Amar Gajjar, Alberto Broniscer
Affiliations
Clinical Trial

Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma

Atmaram S Pai Panandiker et al. Pediatr Blood Cancer. 2014 Jul.

Abstract

Background: Children with diffuse intrinsic pontine glioma (DIPG) continue to have poor outcomes, and radiotherapy (RT) is the only temporarily effective treatment. In this retrospective analysis, we studied the effect of time from diagnosis to start of RT on event-free survival (EFS) and overall survival (OS) in children with DIPG.

Methods: Records of children (n = 95) with DIPG treated with RT at a single institution between April 1999 and September 2009 were analyzed. RT was delivered at doses of 54.0-55.8 Gy at 1.8 Gy per fraction, and children were followed prospectively. The effect of gender, race, interruption during treatment course, age at diagnosis, duration of symptoms prior to diagnosis, use of protocol-based chemotherapy, and time from diagnosis to initiation of RT on EFS and OS was assessed by the Cox proportional hazards model.

Results: Time as a continuous variable from diagnosis to start of RT did not affect outcome. Time dichotomized to ≤14 days significantly affected OS (hazard ratio [HR] = 1.70, P = 0.014) and race other than white or black affected EFS (HR = 2.32, P = 0.017). The 95 patients had a 6-month EFS and OS of 60 ± 5% and 94.7 ± 2.3%, respectively, and a 12-month EFS and OS of 11.6 ± 3.1% and 49.5 ± 5%, respectively.

Conclusions: Time as a continuous variable did not affect OS or EFS in our cohort; however, children treated within 2 weeks of diagnosis had poor outcomes. Although rapid initiation of RT is desirable, our findings do not support intensive efforts aimed at shortening delays from diagnosis to start of RT.

Keywords: diffuse intrinsic pontine glioma; outcomes; radiotherapy; timing.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

None of the authors have any actual or potential conflicts of interest.

Figures

Figure 1
Figure 1
Event-free survival and overall survival of patients (n = 95).
Figure 2
Figure 2
Figure 2A & 2B. Hazard ratio with 95% confidence interval showing effect of gender, race, interruption during radiotherapy, age at diagnosis, duration of symptoms prior to diagnosis, use of protocol-based chemotherapy, radiotherapy (RT) dose, and time intervals from diagnosis to RT on (A) event-free and (B) overall survival. Relevant p-values are shown above each variable.
See this image and copyright information in PMC

References

    1. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–248. - PubMed
    1. Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer. 2000;88(3):685–692. - PubMed
    1. Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–4768. - PMC - PubMed
    1. Chassot A, Canale S, Varlet P, et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2012;106(2):399–407. - PubMed
    1. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol. 2011;13(4):410–416. - PMC - PubMed

Publication types